EHA Library - The official digital education library of European Hematology Association (EHA)

Prioritizing therapies in CLL
EHA Library. Wendtner C. 06/14/17; 185039 Topic: 3Aj Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Clemens Wendtner
Clemens Wendtner
Contributions
Learning Objectives
Barbara Eichhorst - Chair Introduction

Chronic lymphocytic leukemia (CLL) is a very heterogenous disease. Beyond the two subtypes of CLL with mutated versus unmutated IGHV genes, microenvironmental factors as well as genetic aberrations define multiple subtypes of the disease, which may occur in a single patient. In the first part Prof. Federico Caligaris-Cappio will present data regarding the role of microenvironment regarding CLL development, particularly the role of tumour- associated macrophages (TAMs). Because TAMs critically support the survival and proliferation of CLL cells, research and increasing knowledge about these cells is essential in order to understand not only the mechanism of disease, but also potential therapeutic targets. Prof. Sarka Pospisilova will discuss the predictive and prognostic value of different parameters in CLL patients. Besides clinical and serum parameters, genetic aberrations play a major role in development and further progression of the disease. Some of these parameters are crucial for treatment decision as particularly TP53 disruption. Prof. Clemens Wendtner will not only highlight genetic aberrations, but also clinical factors as age and comorbidity status for the choice of frontline therapy as well as sequence of therapy. All presentations show that the field of CLL is currently undergoing a rapid development in basic and clinical research towards longer lasting disease control, if not cure.

Learning Objectives of the manuscript
After viewing this presentation the participant will be able to:
- To understand the relevance of the microenvironment for the development of CLL as well as for further progression of the disease.
- To learn about the most important prognostic and predictive factors and their relevance for clinical practice.
- To learn about considerations regarding the choice of frontline therapy as well relapse therapy including chemoimunotherapies as well as novel targeted therapies.

Learning Objectives of the presentation
After viewing this presentation the participant will be able to:
- For CLL patients we have to prioritize treatment options based on clinical and novel molecular markers.
- Chemoimmunotherapy remains the standard-of-care for the majority of CLL patients in the frontline setting.
- Novels drugs like ibrutinib, idelalisib and venetoclax are nowadays treatment standards for CLL patients with relapsed/refractory disease.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies